Compare MDBH & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDBH | PSTV |
|---|---|---|
| Founded | 1997 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.0M | 28.1M |
| IPO Year | 2022 | 2016 |
| Metric | MDBH | PSTV |
|---|---|---|
| Price | $3.35 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $55.00 |
| AVG Volume (30 Days) | 4.9K | ★ 178.0K |
| Earning Date | 05-14-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,213,000.00 |
| Revenue This Year | N/A | $13.20 |
| Revenue Next Year | N/A | $261.48 |
| P/E Ratio | $4.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.45 | $0.13 |
| 52 Week High | $5.49 | $8.00 |
| Indicator | MDBH | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 34.28 |
| Support Level | $3.16 | $0.36 |
| Resistance Level | $3.87 | $6.65 |
| Average True Range (ATR) | 0.15 | 0.35 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 82.93 | 8.64 |
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The company operates in two reportable segments: a broker dealer & intellectual property service; and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, commercializing and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).